Pfizer ' s Breast Cancer Drug Combo Falls Short of Survival Goal Pfizer ' s Breast Cancer Drug Combo Falls Short of Survival Goal
Pfizer Inc said on Monday a combination of its breast cancer drug, Ibrance (palbociclib), and fulvestrant was not statistically significant in extending overall survival in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease has progressed after prior endocrine therapy.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Health | Hematology | Hormones | Pfizer | Statistics | Women